SEC Info - NIMCO US, Inc., et al. - ‘3’ for 11/23/16 re: Aimmune Therapeutics, Inc.

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Nestle Health Science US Holdings, Inc.

(Last)

(First)

(Middle)

383 MAIN AVE., 5TH FLOOR

(Street)

NORWALK

06851

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/23/16

3. Issuer Name and Ticker or Trading Symbol
Aimmune Therapeutics, Inc. [ AIMT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,552,084	I	0 ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

1. Name and Address of Reporting Person^*

Nestle Health Science US Holdings, Inc.

(Last)

(First)

(Middle)

383 MAIN AVE., 5TH FLOOR

(Street)

NORWALK

06851

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

NESTLE SA

(Last)

(First)

(Middle)

AVE NESTLE 55

(Street)

VEVEY

CH-1800

(City)

(State)

(Zip)

1. Name and Address of Reporting Person^*

NIMCO US, Inc.

(Last)

(First)

(Middle)

383 MAIN AVE, 5TH FLOOR

(Street)

NORWALK

06851

(City)

(State)

(Zip)

Explanation of Responses:

(1) Held by Nestle Health Science US Holdings, Inc. Nestle Health Science US Holdings, Inc. is wholly owned subsidiary of NIMCO US, Inc., which is a wholly owned subsidiary of Nestle S.A., a publicly traded company. Each of these entities may be deemed to share voting and investment power with respect to all shares held by Nestle Health Science US Holdings, Inc. Each of the filing persons disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Remarks:

	/s/ James Pepin, President	11/23/16
	/s/ David P. Frick, Secretary to the Board of Directors	11/23/16
	/s/ Gary Kirschenbaum, Vice President	11/23/16
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

NIMCO US, Inc., et al. – ‘3’ for 11/23/16 re: Aimmune Therapeutics, Inc.

On: Wednesday, 11/23/16, at 4:49pm ET · For: 11/23/16 · Accession #: 1209191-16-151980 · File #: 1-37519

Previous ‘3’: ‘3’ on / for 6/25/15 · Next: ‘3’ on 2/14/20 for 5/8/19 · Latest: ‘3’ on 4/24/20 for 12/31/18

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents

This ‘3’ Document is an XML Data File that may be rendered in various formats:

NIMCO US, Inc., et al. – ‘3’ for 11/23/16 re: Aimmune Therapeutics, Inc.

On: Wednesday, 11/23/16, at 4:49pm ET · For: 11/23/16 · Accession #: 1209191-16-151980 · File #: 1-37519

Previous ‘3’: ‘3’ on / for 6/25/15 · Next: ‘3’ on 2/14/20 for 5/8/19 · Latest: ‘3’ on 4/24/20 for 12/31/18

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34Filing Table of Contents

This ‘3’ Document is an XML Data File that may be rendered in various formats:

Initial Statement of Beneficial Ownership of Securities by an Insider — Form 3 — SEA’34
Filing Table of Contents